DNER and Merkel cell skin cancer: Targeting these pathways has emerged as a promising therapeutic approach, with BET degraders (e.g., BETd‐246) showing efficacy in disrupting these oncogenic mechanisms, particularly in treatment‐resistant MCC cases [34].